Cerebrospinal fluid cyclic guanosine 3'5' monophosphate levels in Parkinson's disease.
We measured CSF and plasma levels of cGMP in 22 patients with Parkinson's disease (PD) and in 28 age and sex-matched controls. PD patients had similar plasma cGMP levels than those of controls, although they showed a non-significant trend towards higher CSF cGMP levels (P=0.07). PD patients treated with levodopa showed significantly higher CSF cGMP levels than those not treated with this drug (P<0.01), and controls (P<0.01). However, treatment with dopamine agonists did not influence CSF cGMP levels. Plasma and CSF levels of cGMP did not correlate with age at onset, duration, and severity of PD. These results suggest that changes in the concentration of cGMP in CSF of patients with PD are not related with the disease, but rather with levodopa therapy.
Navarro
J A
JA
Department of Biochemistry, Hospital Universitario Doce de Octubre, Madrid, Spain.
Jiménez-Jiménez
F J
FJ
Molina
J A
JA
Benito-León
J
J
Cisneros
E
E
Gasalla
T
T
Ortí-Pareja
M
M
Tallón-Barranco
A
A
de Bustos
F
F
Arenas
J
J
D000368:Aged; D006152:Cyclic GMP / Q000097:blood / Q000134:cerebrospinal fluid*; D018491:Dopamine Agonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000097:blood / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D012642:Selegiline / Q000627:therapeutic use
D018491:Dopamine Agonists; D012642:Selegiline; D007980:Levodopa; D006152:Cyclic GMP